Rheumatoid arthritis

Charting New Paths: Non-TNF's Evolving in Rheumatoid Arthritis Market

Retrieved on: 
星期五, 二月 23, 2024
Therapy, Rheumatology, Rheumatoid arthritis, Physician, Rituximab, Adalimumab, JAK, Health, Patient, MOA, TNF, Research, Pharmaceutical industry

As demand for improved outcomes rises, it is vital for manufacturers to understand the top drivers catalyzing switching decisions in the well-established, yet continually evolving, RA landscape.

Key Points: 
  • As demand for improved outcomes rises, it is vital for manufacturers to understand the top drivers catalyzing switching decisions in the well-established, yet continually evolving, RA landscape.
  • Ongoing research from Spherix Global Insight’s Patient Chart Dynamix™: Rheumatoid Arthritis (US) service, marking its eighth year of tracking the US RA switch market, sheds light on these key treatment trends and leading opportunities for drug manufacturers.
  • While “TNF cycling” remains common, accounting for about one-third of all switches, this trend has been declining since 2017.
  • Brands that excel in these areas are well-positioned to capture market share and reshape treatment approaches.

ASRT Lead Plaintiff Deadline Approaching: Assertio Holdings, Inc. Shareholders Should Contact Robbins LLP for Information About the Class Action Against ASRT

Retrieved on: 
星期四, 二月 22, 2024
Acquisition, Person, Spectrum, FDA, News, Sale, Risk, Suppository, Rheumatoid arthritis, Spectrum Pharmaceuticals, Integration, Patient, LLP, ASRT

Assertio is a commercial pharmaceutical company that purportedly offers differentiated products to patients utilizing a non-personal promotional model.

Key Points: 
  • Assertio is a commercial pharmaceutical company that purportedly offers differentiated products to patients utilizing a non-personal promotional model.
  • What is this Case About: Assertio Holdings, Inc. (ASRT) Allegedly Misled Investors Regarding its Reliance on Indocin and Integration of Spectrum Pharmaceuticals, Inc.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Assertio Holdings, Inc. Shareholders who want to act as lead plaintiff for the class should contact Robbins LLP.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against VNET, Assertio, Cummins, and Brooge and Encourages Investors to Contact the Firm

Retrieved on: 
星期四, 二月 22, 2024
Complaint, Acquisition, Spectrum, FDA, News, Food, BIA, Sale, Fraud, CMI, Adjustment, Risk, Cayman, Suppository, Rheumatoid arthritis, Executive, Spectrum Pharmaceuticals, Patient, ASRT, Security (finance), Facility, EPS, Defendant, Learning, P.C

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • On this news, the Company’s share price fell $0.20, or 3.2% on February 13, 2023, on unusually heavy trading volume.
  • According to the complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Brooge class action go to: https://bespc.com/cases/BROG

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Assertio Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines – ASRT

Retrieved on: 
星期二, 二月 20, 2024
Acquisition, Pomerantz, Court, Person, Spectrum, FDA, Prior, Food, News, Sale, Complaint, District court, Adjustment, Risk, Ext, Suppository, Rheumatoid arthritis, Patient, EPS, Action Replay, Pharmaceutical industry

NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT).

Key Points: 
  • NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT).
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Assertio is a commercial pharmaceutical company that purportedly offers differentiated products to patients utilizing a non-personal promotional model.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

ASSERTIO HOLDINGS, INC. (NASDAQ: ASRT) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Assertio Holdings, Inc.

Retrieved on: 
星期二, 二月 20, 2024
Acquisition, Court, Action Replay, Spectrum, News, Advertising, Sale, Complaint, District court, Risk, Rheumatoid arthritis, Spectrum Pharmaceuticals, Patient, ASRT, Defendant, Security (finance)

If you purchased or acquired Assertio securities, and/or would like to discuss your legal rights and options please visit Assertio Holdings, Inc.

Key Points: 
  • If you purchased or acquired Assertio securities, and/or would like to discuss your legal rights and options please visit Assertio Holdings, Inc.
  • If you wish to serve as lead plaintiff, you must move the Court no later than March 5, 2024.
  • If you purchased or acquired Assertio securities, and/or would like to discuss your legal rights and options please visit Assertio Holdings, Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against VNET, Assertio, Cummins, and Brooge and Encourages Investors to Contact the Firm

Retrieved on: 
星期日, 二月 18, 2024
Complaint, Acquisition, Spectrum, FDA, News, Food, BIA, Sale, Fraud, CMI, Adjustment, Risk, Cayman, Suppository, Rheumatoid arthritis, Executive, Spectrum Pharmaceuticals, Patient, ASRT, Security (finance), Facility, EPS, Defendant, Learning, P.C

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • On this news, the Company’s share price fell $0.20, or 3.2% on February 13, 2023, on unusually heavy trading volume.
  • According to the complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Brooge class action go to: https://bespc.com/cases/BROG

Global Psoriatic Arthritis Drug Landscape Research Report 2024: Comprehensive Insights About 20+ Companies and 25+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
星期三, 三月 6, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Therapy, Acquisition, Arthritis, Psoriasis, Psoriatic arthritis, TEM, Inflammation, Malignancy, News, Atopic dermatitis, Route, Phase II, JAK1, KCNA3, JAK3, Discovery, Cell, Bristol Myers Squibb, Multiple sclerosis, Administration, Cytokine, Rheumatoid arthritis, TYK2, Clinical trial, NDA, Lluís Companys, Immune system, JAK2, Pharmaceutical industry

This report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Psoriatic Arthritis pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Psoriatic Arthritis pipeline landscape.
  • A detailed picture of the Psoriatic Arthritis pipeline landscape is provided which includes the disease overview and Psoriatic Arthritis treatment guidelines.
  • The assessment part of the report embraces, in depth Psoriatic Arthritis commercial assessment and clinical assessment of the pipeline products under development.
  • Psoriatic Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

United States HUMIRA Market Analysis, Size, Forecast, and Insights Report, 2019-2023 and 2024-2032 - ResearchAndMarkets.com

Retrieved on: 
星期五, 三月 1, 2024
Pharmaceutical, Health, Clinical Trials, Psoriatic arthritis, Ulcerative colitis, JIA, Crohn's disease, Psoriasis, Ankylosing spondylitis, Uveitis, Adalimumab, SWOT, Juvenile idiopathic arthritis, UC, AbbVie, Rheumatoid arthritis, Hidradenitis suppurativa, Clinical trial, HS, TNF, Research, Pharmaceutical industry

The "US HUMIRA Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US HUMIRA Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights about HUMIRA for autoimmune uveitis in the US.
  • Further, it also consists of future market assessments inclusive of the HUMIRA market forecast analysis for autoimmune uveitis in the US, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in autoimmune uveitis.
  • What are the other emerging products available and how are these giving competition to HUMIRA for autoimmune uveitis?

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

Retrieved on: 
星期六, 二月 24, 2024
Biotechnology, FDA, Health, Pharmaceutical, Managed Care, Pharmacy, Ulcerative colitis, Psoriasis, Uveitis, Ankylosing spondylitis, Multimedia, TEVA, Marketing, Teva, Partnership, Food, Teva Pharmaceuticals, Volunteering, Biosimilar, IC, Safety, Juvenile idiopathic arthritis, Rheumatoid arthritis, Hidradenitis suppurativa, Patient, Prescription, Environment, Generic drug

Teva is Alvotech’s strategic partner for the exclusive commercialization of SIMLANDI in the United States.

Key Points: 
  • Teva is Alvotech’s strategic partner for the exclusive commercialization of SIMLANDI in the United States.
  • An interchangeable biosimilar may be substituted at the pharmacy without consulting the prescriber, much like generic drugs are routinely substituted for brand name drugs.
  • As the only interchangeable adalimumab biosimilar with the high-concentration formulation, SIMLANDI can be substituted for Humira at the pharmacy level, subject to state pharmacy laws.
  • Alvotech handles development and manufacturing, and Teva is responsible for U.S. commercialization, which leverages Teva’s extensive experience and sales and marketing infrastructure.

Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary

Retrieved on: 
星期二, 二月 20, 2024
FDA, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Certification, Sepsis, Psoriasis, Adolescence, Infection, Adalimumab, Hospital, Intuition, Public sector, TB, Risk, Safety, Arthritis, Rheumatoid arthritis, Hidradenitis suppurativa, Death, Autoimmunity, Patient, Lymphoma, Tuberculosis, Malignancy, TNF, OGN, Pharmaceutical industry

Organon (NYSE: OGN), a global healthcare company with a dedicated commitment to biosimilars, announced that the US Department of Veterans Affairs (VA) has exclusively selected HADLIMA in replacement of HUMIRA (adalimumab) for the VA National Formulary.

Key Points: 
  • Organon (NYSE: OGN), a global healthcare company with a dedicated commitment to biosimilars, announced that the US Department of Veterans Affairs (VA) has exclusively selected HADLIMA in replacement of HUMIRA (adalimumab) for the VA National Formulary.
  • "America’s veterans deserve access to quality medicines at a lower cost.
  • “We applaud the VA for its leadership in championing biosimilars and including all three of Organon’s biosimilars available in the US on its formulary."
  • HADLIMA was launched in the US to offer patients a more affordable option without compromising on safety and efficacy.